These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 15990860)

  • 21. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
    Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytogenetic studies in patients on imatinib.
    Deininger MW
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):50-5. PubMed ID: 12783376
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
    Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
    Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
    Miething C; Grundler R; Mugler C; Brero S; Hoepfl J; Geigl J; Speicher MR; Ottmann O; Peschel C; Duyster J
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4594-9. PubMed ID: 17360569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
    Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; Dazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM
    Haematologica; 2003 Mar; 88(3):260-7. PubMed ID: 12651263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Centrosome aberrations in chronic myeloid leukemia correlate with stage of disease and chromosomal instability.
    Giehl M; Fabarius A; Frank O; Hochhaus A; Hafner M; Hehlmann R; Seifarth W
    Leukemia; 2005 Jul; 19(7):1192-7. PubMed ID: 15858613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roots of imatinib resistance: a question of self-renewal?
    Burchert A
    Drug Resist Updat; 2007; 10(4-5):152-61. PubMed ID: 17683977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
    Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
    Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib. Novartis.
    Radford IR
    Curr Opin Investig Drugs; 2002 Mar; 3(3):492-9. PubMed ID: 12054102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
    Meeus P; Demuynck H; Martiat P; Michaux L; Wouters E; Hagemeijer A
    Leukemia; 2003 Feb; 17(2):465-7. PubMed ID: 12592350
    [No Abstract]   [Full Text] [Related]  

  • 36. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].
    Jinnai I
    Nihon Rinsho; 2002 Jan; 60(1):88-94. PubMed ID: 11808344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.